[Effectiveness of the use of Staphylococcus aureus 209 mutant UV-2 at different stages of screening of new antineoplastic antibiotics].
D000190:Actinomyces / Q000378:metabolism*; D000362:Agar; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000096:biosynthesis / Q000494:pharmacology* / Q000627:therapeutic use; D003470:Culture Media; D003609:Dactinomycin / Q000494:pharmacology; D003864:Depression, Chemical; D005827:Genetics, Microbial; D008034:Lincomycin / Q000494:pharmacology; D009154:Mutation; D009355:Neomycin / Q000494:pharmacology; D009848:Olivomycins / Q000494:pharmacology; D010118:Oxytetracycline / Q000494:pharmacology; D013210:Staphylococcus / Q000187:drug effects* / Q000254:growth & development; D013752:Tetracycline / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D003470:Culture Media; D003609:Dactinomycin; D009848:Olivomycins; D000362:Agar; D008034:Lincomycin; D013752:Tetracycline; D009355:Neomycin; D010118:Oxytetracycline
Effektivnost' ispol'zovaniia mutanta zolotistogo stafilokokka (Staph, aureus 209) UF-2 razlichnykh etapakh izyskaiia novykh protivoopukho levykh antibiotikov.